Complex Acid-Base & Electrolyte Disorders in Renal Replacement Therapy: A Clinical Review

Dr Neeraj Manikath , claude.ai

Abstract

Renal replacement therapy (RRT) profoundly alters acid-base homeostasis and electrolyte metabolism through mechanisms extending beyond simple solute removal. This review examines contemporary challenges in managing metabolic complications of RRT, including regional citrate anticoagulation-induced alkalosis, the evolving understanding of uremic acidosis patterns, dysnatremias during continuous therapies, phosphate kinetics paradoxes, and beta-2 microglobulin amyloidosis. We provide evidence-based approaches with practical clinical pearls for internists managing these complex disorders.

Regional Citrate Anticoagulation (RCA) Metabolic Complications: Ionized Hypocalcemia & Metabolic Alkalosis

Regional citrate anticoagulation has emerged as the preferred anticoagulation strategy for continuous renal replacement therapy (CRRT), offering superior filter longevity and reduced bleeding risk compared to systemic heparin.1,2 However, RCA introduces unique metabolic complications that require sophisticated understanding and monitoring.

Citrate Metabolism and Calcium Chelation

Citrate functions by chelating ionized calcium in the extracorporeal circuit, creating a local anticoagulant effect. Trisodium citrate (most common formulation) binds calcium in a 1:1 molar ratio, forming calcium-citrate complexes that render calcium unavailable for the coagulation cascade.3 The citrate-calcium complexes are then removed by the filter and replaced systemically via calcium infusion protocols.

Pearl: Each molecule of citrate metabolized generates three bicarbonate molecules, making citrate a potent alkali load. In patients with preserved hepatic function, citrate metabolism occurs primarily in the liver via the Krebs cycle, with additional metabolism in skeletal muscle and kidneys.4

Ionized Hypocalcemia: The Dual Mechanism

Ionized hypocalcemia during RCA occurs through two distinct mechanisms:

Systemic citrate accumulation (citrate lock): When citrate delivery exceeds metabolic capacity, unmetabolized citrate chelates systemic calcium. This occurs in hepatic dysfunction, shock states with hypoperfusion, or excessive citrate delivery rates.5
Inadequate calcium replacement: Simple under-replacement relative to calcium removal in the ultrafiltrate.

Clinical Hack: The ratio of total calcium to ionized calcium (normally 2:1) becomes a diagnostic tool. A total/ionized calcium ratio >2.5 suggests citrate accumulation, as citrate chelates ionized calcium while total calcium (which includes bound forms) remains artificially elevated.6 This is the "citrate gap."

Bedside Monitoring Strategy:

Ionized calcium: Measure post-filter (should be 0.25-0.35 mmol/L) and systemic (target 1.0-1.2 mmol/L)
Total calcium: Systemic measurement
Calculate total/ionized ratio every 4-6 hours
If ratio >2.5 or systemic ionized calcium <0.9 mmol/L despite calcium infusion, reduce citrate flow by 20-30%5,7

Oyster: Beware the patient with severe lactic acidosis or liver failure receiving RCA. Citrate clearance may be reduced by 75%, necessitating either switching to heparin anticoagulation or using modified low-citrate protocols with citrate flows of 1.5-2.0 mmol/L rather than standard 3-4 mmol/L.8

Metabolic Alkalosis: The Underappreciated Complication

Metabolic alkalosis during RCA results from complete citrate metabolism generating bicarbonate. Unlike spontaneous metabolic alkalosis, RCA-induced alkalosis is euvolemic and associated with normal chloride levels, making it diagnostically distinct.9

Pathophysiology: Each liter of 4% trisodium citrate solution provides approximately 136 mmol of citrate, potentially generating 408 mmol of bicarbonate if completely metabolized—equivalent to administering multiple ampules of sodium bicarbonate hourly.

Clinical Manifestations:

pH >7.50 with bicarbonate >32 mmol/L
Leftward shift of oxygen-hemoglobin dissociation curve (impaired tissue oxygen delivery)
Hypokalemia (intracellular potassium shift)
Ionized hypocalcemia (pH-dependent calcium binding to albumin)
Cardiac arrhythmias in susceptible patients10

Management Pearls:

Pre-emptive dialysate adjustment: Use low-bicarbonate (22-25 mmol/L) or bicarbonate-free dialysate with CRRT to counterbalance citrate-generated alkali11
Citrate flow reduction: Decrease citrate flow to minimum required for anticoagulation (target post-filter ionized calcium 0.25-0.35 mmol/L)
Blood flow optimization: Higher blood flow rates reduce citrate concentration needed for anticoagulation12

Novel Approach: Some centers employ real-time metabolic alkalosis prediction models using citrate flow rates, blood flow, and effluent rates to prospectively adjust dialysate composition, reducing alkalosis incidence by 40%.13

The "Uremic Acidosis" Myth: High Anion Gap vs. Normal Anion Gap Patterns on CRRT

The traditional teaching that uremia uniformly causes high anion gap metabolic acidosis (HAGMA) requires critical re-examination in the era of modern RRT.14

Reconceptualizing Uremic Acidosis

Advanced chronic kidney disease (CKD) typically presents with normal anion gap metabolic acidosis (NAGMA), not HAGMA. This reflects impaired renal ammoniagenesis and bicarbonate reabsorption rather than accumulation of unmeasured anions.15,16

The Anion Gap Paradox: In CKD stages 3-4, the anion gap often decreases due to:

Hypoalbuminemia (albumin is a major unmeasured anion)
Retention of unmeasured cations (calcium, magnesium)
Laboratory artifacts in anion gap calculation17

Clinical Pearl: For every 1 g/dL decrease in albumin below 4 g/dL, add 2.5 mEq/L to the measured anion gap to calculate the "corrected" anion gap.18 Many apparently normal anion gaps in uremia are actually elevated when corrected for hypoalbuminemia.

HAGMA in ESRD: When Does It Occur?

True HAGMA in end-stage renal disease occurs in specific circumstances:

Acute decompensation: Lactic acidosis from sepsis or shock
Ketoacidosis: Diabetic or starvation ketoacidosis superimposed
Toxic ingestions: Methanol, ethylene glycol (less common with RRT)
Severe hyperphosphatemia: Phosphate as an unmeasured anion
Sulfate accumulation: In acute kidney injury with muscle breakdown19

Bedside Hack: The "delta-delta" (Δ-Δ) calculation identifies mixed disorders:

Calculate Δ anion gap: (Measured AG - 12)
Calculate Δ bicarbonate: (24 - Measured HCO₃⁻)
Ratio Δ-AG/Δ-HCO₃⁻:
- <1: NAGMA coexists with HAGMA
- 1-2: Pure HAGMA
- 2: HAGMA with concurrent metabolic alkalosis20

Acid-Base During CRRT: The Underappreciated Variables

Oyster: CRRT itself generates acid-base disturbances independent of the underlying disease:

Lactate-buffered replacement fluid: Lactate must be metabolized to bicarbonate. In shock states with impaired lactate metabolism, this causes worsening acidosis despite RRT.21 Solution: Use bicarbonate-buffered solutions in shock or liver failure.
Bicarbonate loss in effluent: High-volume hemofiltration removes significant bicarbonate (approximately 25 mmol/L in effluent), potentially causing or worsening metabolic acidosis if not replaced adequately.22
Dilutional acidosis: Rapid plasma refilling from interstitial space dilutes bicarbonate concentration.

Clinical Approach to Acidosis on CRRT:

Anion Gap Pattern	Likely Etiology	Management Strategy
Normal AG, low HCO₃⁻	RRT-induced, GI losses	Increase dialysate HCO₃⁻ to 32-35 mmol/L
High AG, low HCO₃⁻	Lactic acidosis, ketoacidosis	Treat underlying cause; consider bicarbonate buffer
High AG, normal HCO₃⁻	Concurrent metabolic alkalosis	Adjust citrate if using RCA; reduce dialysate HCO₃⁻

Evidence-Based Target: Maintain pH 7.32-7.42 and bicarbonate 22-26 mmol/L during CRRT. Both extreme acidosis (pH <7.20) and alkalosis (pH >7.50) increase mortality.23

Dysnatremias During Continuous Therapies: Sodium Sieving & Conductivity Prescriptions

Dysnatremias represent a frequently overlooked complication of continuous RRT, with mechanisms distinct from conventional intermittent hemodialysis.

Sodium Sieving: The Convective Transport Phenomenon

Definition: Sodium sieving refers to the preferential movement of sodium across high-flux membranes during convective therapies (hemofiltration, hemodiafiltration).24

Mechanism: Water moves more rapidly through membrane pores than sodium due to convective drag. This creates a transient sodium concentration gradient, with ultrafiltrate sodium typically 2-5 mmol/L lower than plasma sodium.25 Over hours, this difference becomes clinically significant.

Pearl: In continuous venovenous hemofiltration (CVVH) with high ultrafiltration rates (>35 mL/kg/h), sodium sieving can remove an additional 200-300 mmol sodium per day beyond predictions based on plasma sodium concentration alone.26

Clinical Implication: Patients with hypernatremia may have slower correction than expected, while patients with normal sodium may drift toward hyponatremia during high-volume hemofiltration.

Conductivity-Based Sodium Prescriptions

Modern CRRT machines utilize conductivity measurements to adjust dialysate and replacement fluid sodium concentrations dynamically.27

How It Works:

Conductivity (measured in mS/cm) correlates with ionic strength, predominantly determined by sodium and chloride
Target conductivity set by clinician (typically 14.0-14.6 mS/cm, corresponding to 135-145 mmol/L sodium)
Machine adjusts sodium delivery to achieve target conductivity28

Oyster: Conductivity measurements are confounded by other ions. Severe hyperkalemia, hypercalcemia, or uremia falsely elevate conductivity, potentially leading to inadvertent hyponatremia if machines over-compensate by reducing sodium delivery.29

Clinical Hack for Dysnatremia Management:

For Hyponatremia:

Set dialysate sodium 10 mmol/L higher than plasma sodium
Limit correction to 6-8 mmol/L per 24 hours (osmotic demyelination risk)
Monitor sodium every 4-6 hours
Reduce ultrafiltration rate if volume removal not required30

For Hypernatremia:

Set dialysate sodium equal to plasma sodium initially
Gradually reduce by 2-3 mmol/L every 8-12 hours
Target correction rate: 0.5 mmol/L/hour (maximum)
Increase free water in replacement fluid if using pre-dilution CVVH31

Bedside Formula: Predicted sodium change during CRRT: ΔNa = (Dialysate Na - Plasma Na) × (Effluent Rate / Total Body Water)

For a 70 kg patient (TBW ≈ 42 L) receiving 2 L/hour effluent: ΔNa/hour = (Dialysate Na - Plasma Na) × (2/42) ≈ 0.05 × sodium gradient

The "Isotonic CRRT" Myth

Critical Misconception: Many clinicians assume isotonic dialysate prevents dysnatremia. However, three factors invalidate this assumption:

Definition variability: "Isotonic" (280-295 mOsm/kg) doesn't specify sodium concentration
Non-sodium osmoles: Glucose in dialysate contributes osmolality but not tonicity
Time-dependent equilibration: Initial isotonicity doesn't guarantee sustained eunatremia over days32

Evidence-Based Recommendation: Measure plasma sodium every 4-6 hours during the first 24 hours of CRRT, then every 8-12 hours once stable. Adjust dialysate sodium prescriptions based on measured plasma sodium, not assumed isotonicity.

Phosphate Kinetics in Extended Dialysis: Rebound Hyperphosphatemia & Refractory Hypophosphatemia

Phosphate management during RRT exemplifies the complex interplay between removal, distribution, and mobilization kinetics.

The Three-Pool Phosphate Model

Understanding phosphate kinetics requires appreciating three distinct compartments:33

Plasma (0.1% of total body phosphate): Rapidly equilibrating, dialyzable
Extracellular fluid/soft tissue (15%): Intermediate equilibration (hours)
Bone (85%): Slow equilibration (days to weeks)

Pearl: Plasma phosphate represents only the tip of the iceberg. Aggressive phosphate removal during dialysis depletes plasma and ECF pools but minimally impacts total body phosphate burden, leading to post-dialysis rebound.34

Rebound Hyperphosphatemia

Definition: Post-dialysis increase in serum phosphate of >0.5 mg/dL within 2-4 hours of dialysis completion, occurring in 70-90% of patients.35

Mechanisms:

Transcellular shift: Phosphate moves from intracellular space to extracellular space along concentration gradient after dialysis removes extracellular phosphate
Bone mobilization: Osteoclastic activity releases phosphate from bone mineral
Continued dietary absorption: Ongoing GI phosphate absorption36

Bedside Hack: The "phosphate rebound ratio" predicts interdialytic hyperphosphatemia:

Rebound Ratio = (Post-dialysis PO₄ at 2 hours - Post-dialysis PO₄ at 0 hours) / Pre-dialysis PO₄
Ratio >0.3 predicts poor interdialytic control and increased cardiovascular calcification risk37

Clinical Management Strategies:

Extended dialysis time: Longer sessions allow intracellular-to-extracellular equilibration during treatment, reducing rebound by 30-40%38
Increased dialysis frequency: More frequent (daily or alternate-day) short sessions maintain lower average phosphate levels39
Phosphate binders: Continue binders with meals even on dialysis days
Nocturnal hemodialysis: 6-8 hour overnight sessions achieve superior phosphate control with minimal rebound40

Novel Approach: "Phosphate kinetic modeling" uses pre-dialysis, intra-dialysis (2-hour), and post-dialysis (2-hour) phosphate measurements to calculate phosphate generation rate and optimize dialysis prescription individually.41

Refractory Hypophosphatemia on CRRT

Paradox: While intermittent hemodialysis causes hyperphosphatemia, continuous therapies frequently induce hypophosphatemia, affecting 40-80% of CRRT patients.42

Mechanisms:

Continuous phosphate removal: 24-hour phosphate clearance during CRRT (30-50 mmol/day) exceeds normal dietary intake (25-30 mmol/day)43
Nutritional inadequacy: Critical illness reduces oral intake; parenteral nutrition often phosphate-deficient
Cellular uptake: Refeeding, insulin administration, and cellular recovery increase phosphate demand
Hemofiltration vs. hemodialysis: Pure hemofiltration removes phosphate more efficiently than diffusive hemodialysis due to convective clearance44

Clinical Consequences:

Respiratory muscle weakness (difficult ventilator weaning)
Cardiac dysfunction (reduced contractility)
Impaired cellular ATP production
Increased infection risk (impaired leukocyte function)45

Oyster: Target phosphate levels during CRRT differ from stable CKD. While hyperphosphatemia (>5.5 mg/dL) is harmful in CKD, hypophosphatemia (<2.5 mg/dL) is more dangerous in acute critical illness.46

Management Algorithm:

Mild Hypophosphatemia (2.0-2.5 mg/dL):

Increase nutritional phosphate: Enteral 1500-2000 mg/day, parenteral 30-45 mmol/day
Consider phosphate-supplemented dialysate (custom formulation)47

Moderate Hypophosphatemia (1.5-2.0 mg/dL):

IV phosphate supplementation: 0.32 mmol/kg over 6 hours
Reduce CRRT effluent rate by 20% if clinically feasible
Monitor every 6 hours

Severe Hypophosphatemia (<1.5 mg/dL):

Aggressive IV phosphate: 0.64 mmol/kg over 6 hours
Consider temporary CRRT interruption (4-6 hours) if hemodynamically stable
Rule out refeeding syndrome
Add phosphate to dialysate (1.0-1.5 mmol/L) if available48

Clinical Hack: For patients with persistent hypophosphatemia despite supplementation, add phosphate directly to replacement fluid bags:

Standard potassium phosphate: 3 mmol PO₄/mL
Add 15-20 mL (45-60 mmol) to each 5-liter replacement fluid bag
Achieves dialysate phosphate concentration of approximately 1.0-1.2 mmol/L49

Evidence-Based Target: Maintain phosphate 2.5-4.5 mg/dL during CRRT to optimize cellular function while avoiding toxicity.50

Beta-2 Microglobulin Amyloidosis in Long-Term Hemodialysis: Diagnosis & Novel Adsorption Columns

Dialysis-related amyloidosis (DRA) represents a long-term complication of maintenance hemodialysis, caused by accumulation and deposition of beta-2 microglobulin (β2M) as amyloid fibrils.51

Pathophysiology of β2M Accumulation

β2M Basics:

Low molecular weight protein (11.8 kDa)
Light chain component of MHC class I molecules
Normally filtered by glomeruli and reabsorbed/catabolized by proximal tubules
Serum levels in ESRD: 40-60 mg/L (normal: 1-3 mg/L)52

Why Conventional Dialysis Fails:

Middle molecule characteristics: β2M molecular weight exceeds optimal removal range of standard low-flux membranes (cutoff ~15 kDa)53
Convective dependence: β2M requires convective transport for efficient removal; pure diffusive dialysis is inadequate
Generation rate exceeds clearance: β2M production (150-200 mg/day) exceeds conventional hemodialysis removal (100-150 mg/day)54

Pearl: Dialysis vintage >5-7 years dramatically increases DRA risk. Prevalence: 20% at 5 years, 50% at 10 years, >90% at 20 years on conventional hemodialysis.55

Clinical Manifestations: The CARPAL Syndrome

Classic Triad:

Carpal tunnel syndrome: Most common initial manifestation (median nerve compression)
Arthropathy: Shoulder, wrist, knee—destructive arthropathy with effusions
Bone cysts: Subchondral bone cysts visible on imaging56

Extended Manifestations (CARPAL acronym):

Carpal tunnel syndrome
Arthropathy (large joints)
Radiculopathy (cervical spine)
Pathologic fractures (femoral neck common)
Amyloid deposits (periarticular, visceral)
Lambda light chains (differential diagnosis consideration)57

Oyster: Visceral deposition occurs but is rarely symptomatic. Cardiac involvement in DRA is much less common than in AL or AA amyloidosis. Gastrointestinal involvement can cause pseudo-obstruction or perforation.58

Diagnostic Approach

Clinical Suspicion:

Dialysis vintage >5 years
Bilateral carpal tunnel syndrome
Chronic joint pain and stiffness
Bone cysts on imaging

Imaging:

Radiography: Subchondral cysts in carpal bones, femoral head, acetabulum
MRI: High signal intensity in bones/joints on T2-weighted images; periarticular masses
Ultrasound: Synovial thickening, effusions59

Definitive Diagnosis:

Tissue biopsy: Synovium, carpal tunnel tissue, or bone
Congo red staining: Apple-green birefringence under polarized light
Immunohistochemistry: Specific anti-β2M antibodies confirm β2M amyloid (not AL, AA, or other types)60

Serum β2M Levels:

Useful for screening and monitoring treatment response
Levels >30 mg/L indicate high risk for DRA
Target: Reduce β2M to <20 mg/L with enhanced clearance strategies61

Clinical Hack: In patients with established DRA, measure serum β2M every 6 months. A decrease >30% from baseline indicates effective enhanced clearance; stable or rising levels warrant intensification of clearance strategy.

Treatment Strategies: Beyond Conventional Dialysis

1. High-Flux Hemodialysis with Convection

Modern synthetic membranes (polysulfone, polyamix) with high flux characteristics improve β2M clearance by 30-50% compared to low-flux membranes.62

Key Features:

Membrane surface area >1.8 m²
Ultrafiltration coefficient >40 mL/hour/mmHg
β2M clearance: 40-60 mL/min (vs. 10-20 mL/min with low-flux)

Evidence: The HEMO study demonstrated reduced DRA progression with high-flux membranes in patients with dialysis vintage >3 years.63

2. Hemodiafiltration (HDF): The Gold Standard

Mechanism: Combines diffusive and convective transport with high-volume convection (>20 L per session).

β2M Clearance:

Online HDF: 70-100 mL/min β2M clearance
Reduction ratio: 70-80% per session
Superior to high-flux hemodialysis by 40-60%64

Clinical Evidence:

ESHOL trial: Online HDF reduced all-cause mortality by 30% vs. conventional HD, with significant reductions in carpal tunnel surgery rates65
Turkish HDF Study: β2M levels decreased from 42±8 mg/L to 28±6 mg/L after 12 months of HDF66

Pearl: Post-dilution HDF achieves superior β2M clearance compared to pre-dilution HDF due to higher effective blood water flow through the filter without dilution.

3. β2M Adsorption Columns: Novel Technology

Mechanism: Specific columns containing ligands that selectively bind and remove β2M from blood passing through the column during dialysis.67

Available Technologies:

a) Lixelle β2M Column (Japan):

Contains cellulose beads with immobilized antibodies against β2M
Direct hemoperfusion or inline with dialysis circuit
Single-use column
β2M reduction: 60-70% per session
Clinical use: Approved in Japan since 1996; reduces joint pain and radiologic progression68,69

b) Hemophan-Based Adsorption:

Modified hemophan membrane with enhanced β2M binding capacity
Integrated into hemodialysis session
β2M reduction: 40-50% per session70

Clinical Evidence for Adsorption:

Japanese Registry Data:

2,400 patients using Lixelle columns
Symptom improvement: 65% reported reduced joint pain
Reduced carpal tunnel surgery rate by 50% compared to conventional HD
Bone cyst regression in 30% of patients with <5 years DRA71

Limitations:

Cost: $200-300 per column (single use)
Not widely available outside Japan
Insurance coverage limited
Requires 2-3 times weekly use for sustained benefit72

Oyster: β2M adsorption columns are synergistic with HDF. Combined therapy (HDF + adsorption weekly) achieves β2M levels <25 mg/L in 80% of patients, compared to 50% with HDF alone.73

4. Kidney Transplantation: The Ultimate Solution

Successful kidney transplantation normalizes β2M levels within 1-3 months and halts DRA progression.74

Evidence:

β2M levels: Decrease from 40-50 mg/L pre-transplant to 2-4 mg/L post-transplant
Symptom improvement: 70% report reduced joint pain within 6 months
Radiologic stabilization: Cysts stop growing but rarely regress
New DRA manifestations: Extremely rare post-transplant75

Pearl: Transplant before DRA develops is the most effective prevention strategy. Patients with living donors should be encouraged toward preemptive or early transplantation.

Evidence-Based Prevention and Management Algorithm

Primary Prevention (all HD patients):

Use high-flux synthetic membranes from dialysis initiation
Online HDF if available and suitable
Ultrapure dialysate to reduce inflammatory cytokines that promote β2M production76
Optimize dialysis adequacy (Kt/V >1.4)
Consider more frequent dialysis (5-6 times weekly) if feasible

For Established DRA:

Switch to online HDF (post-dilution, >20 L convection volume)
Consider β2M adsorption columns if available (1-2 times weekly)
Symptom management: NSAIDs, corticosteroid injections for acute flares
Surgical intervention: Carpal tunnel release, joint replacement if disabling
Active pursuit of kidney transplantation77

Monitoring Strategy:

Serum β2M every 6 months
Annual shoulder radiographs (cysts are early markers)
Clinical assessment for carpal tunnel symptoms biannually

Future Directions:

Novel β2M-binding polymers in development
Gene therapy to reduce β2M production
Small molecules that inhibit β2M fibrillogenesis
Enhanced convective therapies (expanded hemodialysis)78

Conclusion

Management of acid-base and electrolyte disorders during RRT requires nuanced understanding that extends beyond simple dialysis prescriptions. Regional citrate anticoagulation demands vigilant monitoring for metabolic alkalosis and citrate accumulation. The traditional concept of uniform uremic acidosis has evolved to recognize distinct anion gap patterns requiring individualized management. Dysnatremias during continuous therapies reflect complex sodium sieving and conductivity-based mechanisms. Phosphate kinetics demonstrate paradoxical patterns between intermittent and continuous modalities, necessitating opposing management strategies. Finally, long-term hemodialysis patients face progressive β2M amyloidosis, increasingly manageable with enhanced clearance strategies and novel adsorption technologies.

Internists caring for RRT patients must move beyond cookbook prescriptions to embrace physiologically-informed, dynamically adjusted approaches that anticipate and prevent these complications. The integration of bedside clinical acumen with sophisticated understanding of solute kinetics, membrane physics, and metabolic consequences defines excellence in modern dialysis care.

References

Oudemans-van Straaten HM, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545-552.
Gattas DJ, et al. Systematic review and meta-analysis of anticoagulation in critically ill patients receiving continuous renal replacement therapy. Intensive Care Med. 2014;40(11):1611-1619.
Morgera S, et al. Pilot study on the effects of regional citrate anticoagulation during continuous venovenous hemodialysis on acid-base balance. Int J Artif Organs. 2005;28(1):39-43.
Kramer L, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450-2455.
Hetzel GR, et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006;48(5):806-811.
Meier-Kriesche HU, et al. Pharmacokinetics of citrate in patients with acute renal failure undergoing continuous venovenous hemodialysis. Crit Care Med. 2001;29(1):118-123.
Link A, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care. 2012;16(3):R97.
Schneider AG, et al. Liver dysfunction and its association with outcomes in critically ill patients with acute kidney injury receiving continuous renal replacement therapy: a multicenter retrospective cohort study. Crit Care. 2017;21(1):172.
Mukhopadhyay A, et al. Association of modified citrate anticoagulation with metabolic alkalosis in patients receiving continuous venovenous hemofiltration. Nephrology. 2004;9(4):233-239.
Tolwani A, et al. Incidence and risk factors for metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Clin J Am Soc Nephrol. 2008;3(6):1763-1767.
Mitchell A, et al. Prospective controlled trial of citrate versus heparin anticoagulation in continuous venovenous hemofiltration: influence on coagulation cascade, hemodynamics, and metabolic complications. Intensive Care Med. 2003;29(4):641-648.
Morabito S, et al. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9(12):2173-2188.
Zhang Z, et al. Predictive analytics for metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2019;47(12):e987-e994.
Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2016;67(2):307-317.
Bushinsky DA, et al. Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol. 1983;245(2):F204-F209.
Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(2):263-275.
Figge J, et al. Anion gap and hypoalbuminemia. Crit Care Med. 1998;26(11):1807-1810.
Durfey N, et al. Albumin-corrected anion gap in end-stage renal disease. Clin Chim Acta. 2018;481:172-177.
Forni LG, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43(6):855-866.
Emmett M, Narins RG. Clinical use of the anion gap. Medicine. 1977;56(1):38-54

Search This Blog

Internal medicine